The latest release of Genedata Biologics is an important milestone in realizing that strategic goal, which promotes adoption of new collaboration models based on technology transfer, division-of-labor, and technology in-licensing.
Basel, Switzerland (PRWEB) July 06, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™ 1.5, the latest version of its enterprise solution for biologics R&D. The new Genedata Biologics provides support for cross-departmental and external data exchange as well as technology transfers among research partners, such as pharmaceutical and biotech companies, technology providers, contract research organizations (CROs), and academic research networks. Genedata Biologics was specifically designed to support Open Innovation models.
Genedata Biologics is a first-in-class, off-the-shelf software solution for integrated data management and analysis of biologics R&D activities. It streamlines and automates the biologics lead generation and optimization process, including antibody screening, protein engineering, and protein production. These capabilities enable pharmaceutical and biotechnology R&D organizations to more efficiently discover and develop novel protein-based therapies.
Open Innovation Support
Supporting Open Innovation models, Genedata Biologics 1.5 simplifies data exchange by providing a collaboration platform for pharmaceutical, biotechnology, and technology companies, CROs, and academic networks. The platform now facilitates the exchange of raw and result data with standardized data exchange formats for molecule data, sequence data, assay data, and other relevant data types. As an integrated data management platform, Genedata Biologics enables registration and documentation of externally-generated materials and samples such as proteins, DNA and cell lines, including antigen materials, plasmid batches, and antibody libraries.
Genedata Biologics also provides the infrastructure for rapid implementation of corporate-specific workflows and technologies such as proprietary molecule formats, proprietary antibody libraries and display systems, or corporate identifiers. This capability will enable technology providers to easily transfer their technology within partner networks.
“Genedata focuses on providing a complete biologics platform that covers the full R&D process from antibody screening to protein engineering and production,” said Dr. Othmar Pfannes, CEO of Genedata. “The latest release of Genedata Biologics is an important milestone in realizing that strategic goal, which promotes adoption of new collaboration models based on technology transfer, division-of-labor, and technology in-licensing,” continued Pfannes. “Genedata Biologics underscores our commitment to and investments in biopharma manufacturing and emerging biosimilars markets.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US. http://www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
# # #